Related Experiment Video
Updated: Sep 23, 2026
08:15
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
Published on: September 17, 2015
[Efficiency of diovan (valsartane) in arterial hypertension patients]
Meditsina Truda I Promyshlennaia Ekologiia
|July 23, 2003
Insights
Valsartan effectively lowered blood pressure in patients with hypertension in the Far North over four weeks. The medication demonstrated good tolerance and influenced metabolic processes.
Area of Science:
- Cardiology
- Pharmacology
- Environmental Medicine
Background:
- Arterial hypertension is a significant health concern, particularly in challenging environments like the Far North.
- Understanding the impact of antihypertensive medications on circadian blood pressure and metabolic functions is crucial for effective treatment.
- Valsartan is an angiotensin II receptor blocker used to treat hypertension.
Purpose of the Study:
- To evaluate the antihypertensive efficacy and tolerance of Diovan (valsartan) 160 mg/day in patients with mild to moderate arterial hypertension residing in the Far North.
- To assess the influence of valsartan on circadian blood pressure patterns.
- To investigate the effects of valsartan on lipid, carbohydrate, and water-salt metabolism.
Main Methods:
- A 4-week open-label study involving 20 patients with mild to moderate arterial hypertension.
- Administration of Diovan (valsartan) at a dose of 160 mg/day.
- Monitoring of circadian blood pressure, lipid profile, carbohydrate metabolism, and water-salt balance.
Main Results:
- Valsartan demonstrated significant antihypertensive activity.
- The medication was well-tolerated by the study participants.
- Preliminary data suggests an influence on circadian blood pressure and metabolic parameters, requiring further investigation.
Conclusions:
- Valsartan 160 mg/day is an effective treatment for mild to moderate arterial hypertension in patients living in the Far North.
- The drug exhibits good tolerance in this population.
- Further research is warranted to fully elucidate the effects of valsartan on circadian rhythms and metabolic exchanges in this unique environmental context.
Abstract:
Diovan (valsartan) in dose 160 mg/day was given to 20 patients with mild and moderate arterial hypertension living in the Far North. The treatment was carried out during 4 weeks and its influence on circadian BP, lipid, carbohydrate and water-salt exchange was studied. Antihypertensive activity and tolerance to the medication were also analyzed.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...